• IBD-control increased significantly, indicating that patients reported higher levels of control over their disease.
• Self-reported physical activity and social connection increased overall.
• Self-reported wellbeing increased by an average of 17%.
• The overall sentiment from interviews was friendly, positive and encouraging and our courses and wellbeing content was received well by those both in flare and in remission.

• In a survey of 151 people, it was found that 87% have not received external support for their chronic pain and fatigue, yet it is widely sought after.
• The group average of patients’ ACT survey scores significantly improved after completing the programme (n=21, p<0.0001). The results suggest that the programme helped the participants to build acceptance and psychological flexibility, understand more about their chronic symptoms, to feel less alone and that they can live a fulfilling life despite ongoing pain and fatigue.
• IBD-Control scores did not statistically change over the 8-weeks. This result suggests that disease control remained consistent throughout programme.
• The study showed that physical levels of chronic pain and fatigue did not change, as expected. However, self-reported impact suggests that perception of symptoms changed as a result of taking part in the programme.

• Patients taking the courses reported that they helped to change their behaviour through positively impacting their knowledge, beliefs about their capabilities, optimism, beliefs about the health and wellbeing consequences of self-management and their ability to set goals.
• Over 62% of patients reported that they had a positive attitude towards the course that they completed.
• Symptoms and disease activity measured on a validated Patient Reported Outcome Measure remained consistent throughout the trial.
• The overall positive response and acceptability of the technology, both from clinicians and subject matter experts is extremely promising.

We are a multi-award winning and social-impact focused company, developing personalised digital therapies for people living with long-term inflammatory conditions, created by our team of researchers, clinicians and patient groups.